Mirati Therapeutics announced that the U.S. FDA has granted accelerated approval for KRAZATI, a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA-approved test, who have received at least one prior systemic therapy.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRTX:
- Mirati (NASDAQ:MRTX) Stock Jumps as FDA Approves Lung Cancer Drug
- Stifel cuts Mirati price target to $73, says move lower ‘overdone’
- Mirati Therapeutics downgraded to Neutral from Buy at Citi (yesterday)
- Mirati Therapeutics price target lowered to $61 from $100 at BofA
- Mirati Therapeutics downgraded to Neutral from Overweight at JPMorgan